NovoCure Ltd
(MEX:NVCR)
MXN
275.39
0 (0%)
Market Cap: 37.69 Bil
Enterprise Value: 32.64 Bil
PE Ratio: 0
PB Ratio: 5.74
GF Score: 71/100 - Q1 2024 Novocure Ltd Earnings Call TranscriptMay 02, 2024MXN275.39Earnings
- Q4 2023 Novocure Ltd Earnings Call TranscriptFeb 22, 2024MXN275.39Earnings
- Novocure Ltd at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Novocure Ltd at Piper Sandler Healthcare Conference TranscriptNov 29, 2023
- Q3 2023 Novocure Ltd Earnings Call TranscriptOct 26, 2023MXN275.39Earnings
- Novocure Ltd at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Novocure Ltd at Wells Fargo Healthcare Conference TranscriptSep 07, 2023
- Q2 2023 Novocure Ltd Earnings Call TranscriptJul 27, 2023MXN694.37Earnings
- Novocure Ltd LUNAR Phase 3 Clinical Trial Presentation TranscriptJun 06, 2023
- Q1 2023 Novocure Ltd Earnings Call TranscriptMay 04, 2023MXN1080.24Earnings
- Q4 2022 Novocure Ltd Earnings Call TranscriptFeb 23, 2023MXN1555Earnings
- Novocure Ltd at JPMorgan Healthcare Conference TranscriptJan 10, 2023
- Novocure Ltd at Piper Sandler Healthcare Conference TranscriptDec 01, 2022
- Q3 2022 Novocure Ltd Earnings Call TranscriptOct 27, 2022MXN1307.95Earnings
- Novocure Ltd at Wells Fargo Healthcare Conference TranscriptSep 07, 2022
- Q2 2022 Novocure Ltd Earnings Call TranscriptJul 28, 2022MXN1454.46Earnings
- Q1 2022 Novocure Ltd Earnings Call TranscriptApr 28, 2022MXN1614Earnings
- Q4 2021 Novocure Ltd Earnings Call TranscriptFeb 24, 2022MXN1521.03Earnings
- Novocure Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2022
- Novocure Ltd at Piper Sandler Healthcare Conference (Virtual) TranscriptNov 30, 2021
- Q3 2021 Novocure Ltd Earnings Call TranscriptOct 28, 2021Earnings
- Novocure Ltd at Wells Fargo Virtual Healthcare Conference TranscriptSep 10, 2021
- Q2 2021 Novocure Ltd Earnings Call TranscriptJul 29, 2021Earnings
- Q1 2021 Novocure Ltd Earnings Call TranscriptApr 29, 2021Earnings
- Q4 2020 Novocure Ltd Earnings Call TranscriptFeb 25, 2021Earnings
- Novocure Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- Novocure Ltd at Evercore ISI HealthCONx Conference (Virtual) - Fireside Chat TranscriptDec 02, 2020
- Novocure Ltd Virtual Research & Development Day TranscriptNov 12, 2020
- Q3 2020 Novocure Ltd Earnings Call TranscriptOct 29, 2020Earnings
- Novocure Ltd at Wells Fargo Virtual Healthcare Conference TranscriptSep 09, 2020
- Q2 2020 Novocure Ltd Earnings Call TranscriptJul 30, 2020Earnings
- Q1 2020 Novocure Ltd Earnings Call TranscriptApr 30, 2020Earnings
- Q4 2019 Novocure Ltd Earnings Call TranscriptFeb 27, 2020Earnings
- Novocure Ltd at JPMorgan Healthcare Conference TranscriptJan 13, 2020
- Q3 2019 Novocure Ltd Earnings Call TranscriptOct 31, 2019Earnings
- Q2 2019 Novocure Ltd Earnings Call TranscriptJul 25, 2019Earnings
- Q1 2019 Novocure Ltd Earnings Call TranscriptMay 02, 2019Earnings
- Q4 2018 Novocure Ltd Earnings Call TranscriptFeb 28, 2019Earnings
Novocure Ltd at Wells Fargo Healthcare Conference Transcript
Sep 07, 2023 / 04:45PM GMT
Release Date Price:
MXN535
Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst
Good afternoon, everyone. I'm Larry Biegelsen, the medical device analyst at Wells Fargo. It's my pleasure to host this session with NovoCure. With us, we have Bill Doyle, Executive Chairman; Ashley Cordova, the CFO. In terms of format, it's going to be fireside chat. If anybody has a question, please raise your hand, we'll come around. Bill and Ashley, thanks so much for being here.
William F. Doyle
NovoCure Limited - Executive Chairman
Thank you, Larry. Thanks for having us.
Ashley Cordova
NovoCure Limited - CFO
Thanks for having us, Larry.
Questions & Answers
Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst
Of course. So let's start with the INNOVATE-3 top line results that you guys released, I don't know, about a week ago. Bill, maybe just provide us with your perspective
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)